Folgen
Michelle Lai
Michelle Lai
Assistant Professor, Harvard University
Bestätigte E-Mail-Adresse bei bidmc.harvard.edu
Titel
Zitiert von
Zitiert von
Jahr
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
11352019
A survey of liver transplantation from living adult donors in the United States
RS Brown Jr, MW Russo, M Lai, ML Shiffman, MC Richardson, ...
New England Journal of Medicine 348 (9), 818-825, 2003
6012003
The clinical significance of persistently normal ALT in chronic hepatitis B infection
M Lai, BJ Hyatt, I Nasser, M Curry, NH Afdhal
Journal of hepatology 47 (6), 760-767, 2007
4652007
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials
SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ...
Journal of hepatology 73 (1), 26-39, 2020
3732020
GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease
R Loomba, Z Kayali, M Noureddin, P Ruane, EJ Lawitz, M Bennett, ...
Gastroenterology 155 (5), 1463-1473. e6, 2018
3202018
The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase
PJ White, RW McGarrah, PA Grimsrud, SC Tso, WH Yang, JM Haldeman, ...
Cell metabolism 27 (6), 1281-1293. e7, 2018
2802018
Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension
N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ...
Gastroenterology 158 (5), 1334-1345. e5, 2020
2772020
Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
S Gawrieh, M Noureddin, N Loo, R Mohseni, V Awasty, K Cusi, ...
Hepatology 74 (4), 1809-1824, 2021
2692021
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis
P An, LL Wei, S Zhao, DY Sverdlov, KA Vaid, M Miyamoto, K Kuramitsu, ...
Nature communications 11 (1), 2362, 2020
2392020
ChREBP regulates fructose-induced glucose production independently of insulin signaling
MS Kim, SA Krawczyk, L Doridot, AJ Fowler, JX Wang, SA Trauger, ...
The Journal of clinical investigation 126 (11), 4372-4386, 2019
2172019
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis
M Kornek, M Lynch, SH Mehta, M Lai, M Exley, NH Afdhal, D Schuppan
Gastroenterology 143 (2), 448-458, 2012
2162012
Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis
EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Lai
Hepatology 62 (2), 584-590, 2015
2072015
Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016
DH Kaswala, M Lai, NH Afdhal
Digestive diseases and sciences 61, 1356-1364, 2016
1932016
The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease
EB Tapper, T Challies, I Nasser, NH Afdhal, M Lai
Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016
1772016
A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis
EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Chang, M Lai
Clinical Gastroenterology and Hepatology 14 (5), 753-759, 2016
1632016
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
G Garcia-Tsao, J Bosch, Z Kayali, SA Harrison, MF Abdelmalek, E Lawitz, ...
Journal of hepatology 72 (5), 885-895, 2020
1482020
Liver fibrosis determination.
M Lai, NH Afdhal
Gastroenterology Clinics of North America 48 (2), 281-289, 2019
1142019
Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography
EB Tapper, N Sengupta, MMG Hunink, NH Afdhal, M Lai
Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015
892015
Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score
EB Tapper, MGM Hunink, NH Afdhal, M Lai, N Sengupta
PLoS One 11 (2), e0147237, 2016
722016
Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study
EB Tapper, M Lai
Hepatology 63 (4), 1184-1189, 2016
712016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20